Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT02752113

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02752113
  • EudraCT 2016-000242-57
Other papers using this trial's data
  • Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes European heart journal. Cardiovascular pharmacotherapy, 2020-11-01 DOI, PubMed 31816038
  • Is GFR decline induced by SGLT2 inhibitor of clinical importance? Cardiovascular diabetology, 2024-05-29 DOI, PubMed 38811998, PMC11138027 In the PMC Open Access subset under CC BY.
  • Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine Cardiovascular diabetology, 2021-09-04 DOI, PubMed 34481498, PMC8418746 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02752113. Randomized; no masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-11-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Acronym
ELMI
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
Empagliflozin and Linagliptin
Intervention (Drug)
Metformin and Insulin sc
Lead sponsor
Institut für Pharmakologie und Präventive Medizin (class: research network)
Collaborator
University of Erlangen-Nürnberg Medical School (class: other)

Record details

Record id
cardio:ct-nct02752113
Content hash
1a56f6388ae63292b776f059be8f6a9964c184d64ef9617f03753a7b2ff5025c